Triangle Securities Wealth Management reduced its holdings in shares of Pfizer, Inc. (NYSE:PFE) by 3.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 16,216 shares of the biopharmaceutical company’s stock after selling 548 shares during the quarter. Triangle Securities Wealth Management’s holdings in Pfizer were worth $545,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Sphera Funds Management LTD. bought a new position in shares of Pfizer during the 1st quarter worth approximately $13,342,000. Searle & CO. boosted its stake in shares of Pfizer by 92.7% during the 1st quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock worth $2,739,000 after acquiring an additional 38,500 shares during the period. E&G Advisors LP boosted its stake in shares of Pfizer by 6.8% during the 1st quarter. E&G Advisors LP now owns 62,258 shares of the biopharmaceutical company’s stock worth $2,130,000 after acquiring an additional 3,940 shares during the period. Insight 2811 Inc. boosted its stake in shares of Pfizer by 3.7% during the 1st quarter. Insight 2811 Inc. now owns 9,324 shares of the biopharmaceutical company’s stock worth $319,000 after acquiring an additional 329 shares during the period. Finally, Prentiss Smith & Co. Inc. boosted its stake in shares of Pfizer by 1.7% during the 1st quarter. Prentiss Smith & Co. Inc. now owns 14,948 shares of the biopharmaceutical company’s stock worth $511,000 after acquiring an additional 250 shares during the period. Institutional investors own 69.09% of the company’s stock.
Several brokerages have recently commented on PFE. Jefferies Group LLC set a $35.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. Vetr downgraded Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price for the company. in a research note on Wednesday. BMO Capital Markets reiterated a “buy” rating and set a $37.00 target price on shares of Pfizer in a research note on Thursday. Berenberg Bank set a $39.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, August 1st. Finally, Morgan Stanley reiterated a “neutral” rating and set a $35.00 target price (down from $38.00) on shares of Pfizer in a research note on Monday, June 12th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $37.72.
Shares of Pfizer, Inc. (NYSE PFE) traded down 0.76% during trading on Friday, reaching $35.46. The company’s stock had a trading volume of 12,275,326 shares. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $35.84. The stock has a market cap of $210.89 billion, a P/E ratio of 25.94 and a beta of 1.00. The stock has a 50-day moving average of $33.58 and a 200-day moving average of $33.52.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same period last year, the company earned $0.64 earnings per share. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. Analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.58%. The ex-dividend date of this dividend was Wednesday, August 2nd. Pfizer’s payout ratio is currently 94.12%.
In other news, insider Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $34.00, for a total value of $249,900.00. Following the completion of the transaction, the insider now directly owns 124,774 shares of the company’s stock, valued at $4,242,316. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sally Susman sold 38,230 shares of the firm’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the transaction, the insider now directly owns 145,649 shares of the company’s stock, valued at $5,097,715. The disclosure for this sale can be found here. Insiders sold 464,521 shares of company stock valued at $15,813,961 over the last ninety days. Corporate insiders own 0.06% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Pfizer, Inc. (PFE) Shares Sold by Triangle Securities Wealth Management” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/09/15/pfizer-inc-pfe-shares-sold-by-triangle-securities-wealth-management.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.